Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: DWK-1339
  • Price: $650.0/100mg $1100.0/250mg $1900.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao
Related CAS#:
1018946-38-7 197723-00-5
73257-44-0 99273-04-8
124-28-7 64049-97-4
6531-58-4 16976-98-0
25301-02-4 51273-01-9
1158522-08-7 940364-43-2
134104-43-1 1526979-94-1
131615-57-1 6906-52-1
930439-75-1 1018584-77-4
1375289-11-4 849349-65-1

1018946-38-7

1018946-38-7 structure
1018946-38-7 structure
  • Name: DWK-1339
  • Chemical Name: 2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)-1-benzofuran
  • CAS Number: 1018946-38-7
  • Molecular Formula: C20H22O4
  • Molecular Weight: 326.38600
  • Catalog: Signaling Pathways Neuronal Signaling Amyloid-β
  • Create Date: 2016-07-18 16:41:57
  • Modify Date: 2024-01-09 22:15:00
  • DWK-1339 is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
Name 2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)-1-benzofuran
Synonyms DWK-1339
2-(3,4-dimethoxy-phenyl)-5-(3-methoxy-propyl)-benzofuran
UNII-WN8TEM4Q1F
Benzofuran,2-(3,4-dimethoxyphenyl)-5-(3-methoxypropyl)
Description DWK-1339 is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
Related Catalog
Target

Amyloid-β[1]

In Vitro DWK-1339 (MDR-1339) is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50, 31.4 μM). DWK-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. DWK-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity[1].
In Vivo DWK-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (AD), with an ED50 of 0.19 mg/kg. DWK-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation, and reduces the Aβ1-40 and Aβ1-42 levels in APP/PS1 mice[1].
Cell Assay HT22 cells, a murine cell line of hippocampal origin, are grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 5% penicillin/streptomycin. At the outset, 90% confluent cells are dissociated and plated at 5 × 103 cells/well in a 96-well plate. When the cells are attached to the plate, the medium is replaced with plain DMEM. The cells are treated with DWK-1339. One hour after DWK-1339 treatment, 4 μL of pre-diluted 25 μM Aβ42 is added to the media, and the cells are further incubated for 18 h. For the determination of cell viability, 15 μL of 5 mg/mL MTT is added to each well and incubated for 3 h. The formazan that formed is dissolved in DMSO, and the absorbance is measured at 570-630 nm using a plate reader[1].
Animal Admin For this study, a total of 24 (n = 8 for each group) APP/PS1 [B6C3-Tg (APPswe, PSEN1dE9) 85Dbo/J] Tg mice are utilized. The mice are housed in a controlled environment under standard room temperature, relative humidity and a 12 h light/dark cycle with free access to food and water. APP/PS1 treated groups are orally administered with DWK-1339 at a dose of 30 or 100 mg/kg body weight once daily. DWK-1339 treatment is at the age of 29 weeks, and the treatment is conducted for 8 weeks[1].
References

[1]. Ha HJ, et al. Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. J Med Chem. 2018 Jan 11;61(1):396-402.
Molecular Formula C20H22O4
Molecular Weight 326.38600
Exact Mass 326.15200
PSA 40.83000
LogP 4.69600
Storage condition 2-8℃
61222-89-7 structure

61222-89-7

74-88-4 structure

74-88-4

~93%

1018946-38-7 structure

1018946-38-7

Literature: DAEWOONG PHARMACEUTICAL CO., LTD.; MEDIFRON DBT CO., LTD.; CHOI, Soo Jin; LEE, Byung Goo; YOON, Hee Kyoon; LIM, Young Mook; LEE, Joon Hwan; PARK, Sung Woo Patent: WO2014/7554 A1, 2014 ; Location in patent: Paragraph 75-77 ;
61222-89-7 structure

61222-89-7

77-78-1 structure

77-78-1

~93%

1018946-38-7 structure

1018946-38-7

Literature: DAEWOONG PHARMACEUTICAL CO., LTD.; MEDIFRON DBT CO., LTD.; CHOI, Soo Jin; LEE, Byung Goo; YOON, Hee Kyoon; LIM, Young Mook; LEE, Joon Hwan; PARK, Sung Woo Patent: WO2014/7554 A1, 2014 ; Location in patent: Paragraph 89-91 ;
1533435-14-1 structure

1533435-14-1

~%

1018946-38-7 structure

1018946-38-7

Literature: DAEWOONG PHARMACEUTICAL CO., LTD.; MEDIFRON DBT CO., LTD.; CHOI, Soo Jin; LEE, Byung Goo; YOON, Hee Kyoon; LIM, Young Mook; LEE, Joon Hwan; PARK, Sung Woo Patent: WO2014/7554 A1, 2014 ; Location in patent: Paragraph 98-100 ;
7306-46-9 structure

7306-46-9

~%

1018946-38-7 structure

1018946-38-7

Literature: DAEWOONG PHARMACEUTICAL CO., LTD.; MEDIFRON DBT CO., LTD.; CHOI, Soo Jin; LEE, Byung Goo; YOON, Hee Kyoon; LIM, Young Mook; LEE, Joon Hwan; PARK, Sung Woo Patent: WO2014/7554 A1, 2014 ;
1533435-13-0 structure

1533435-13-0

~%

1018946-38-7 structure

1018946-38-7

Literature: DAEWOONG PHARMACEUTICAL CO., LTD.; MEDIFRON DBT CO., LTD.; CHOI, Soo Jin; LEE, Byung Goo; YOON, Hee Kyoon; LIM, Young Mook; LEE, Joon Hwan; PARK, Sung Woo Patent: WO2014/7554 A1, 2014 ;

Chemsrc provides CAS#:1018946-38-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1018946-38-7 | Chemsrc address: https://www.chemsrc.com/en/baike/693107.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved